OBJECTIVES: The aim of the study was to evaluate female sexuality in a selective population of newly diagnosed multiple sclerosis (MS) women. MATERIALS AND METHODS: In this clinic-based study, 63 newly diagnosed consecutive women affected by definite MS were admitted. Disability and depression were evaluated with the expanded disability status scale (EDSS) and Beck depression inventory, respectively. Sexual function was evaluated with the female sexual function index (FSFI). A group of 61 healthy female volunteers with the same baseline characteristics were used as controls. Postmenopausal women and patients with other major concomitant neurological, endocrinological, vascular, gynecological, psychiatric disorders, use of medicines that can cause female sexual dysfunction (FSD) and disease-modifying drugs were excluded from the study. RESULTS: All the evaluated patients were ambulant with no major neurological impairment (mean EDSS score 2.5, range 0-3.5). None of the patients were considered clinically depressed, but some of them were sad or worried. According to the sexual history and FSFI scores, sexual dysfunction was diagnosed in 22 (34.9%) out of the 63 patients and in 13 (21.31%) out of the 61 healthy females (P > 0.05). CONCLUSIONS: In the newly diagnosed MS patients, FSD represent an important issue even though disability and other concomitant disorders affecting sexual function were excluded.
OBJECTIVES: The aim of the study was to evaluate female sexuality in a selective population of newly diagnosed multiple sclerosis (MS) women. MATERIALS AND METHODS: In this clinic-based study, 63 newly diagnosed consecutive women affected by definite MS were admitted. Disability and depression were evaluated with the expanded disability status scale (EDSS) and Beck depression inventory, respectively. Sexual function was evaluated with the female sexual function index (FSFI). A group of 61 healthy female volunteers with the same baseline characteristics were used as controls. Postmenopausal women and patients with other major concomitant neurological, endocrinological, vascular, gynecological, psychiatric disorders, use of medicines that can cause female sexual dysfunction (FSD) and disease-modifying drugs were excluded from the study. RESULTS: All the evaluated patients were ambulant with no major neurological impairment (mean EDSS score 2.5, range 0-3.5). None of the patients were considered clinically depressed, but some of them were sad or worried. According to the sexual history and FSFI scores, sexual dysfunction was diagnosed in 22 (34.9%) out of the 63 patients and in 13 (21.31%) out of the 61 healthy females (P > 0.05). CONCLUSIONS: In the newly diagnosed MSpatients, FSD represent an important issue even though disability and other concomitant disorders affecting sexual function were excluded.
Authors: Giovanni F M Strippoli; Mariacristina Vecchio; Suetonia Palmer; Giorgia De Berardis; Jonathan Craig; Giuseppe Lucisano; David Johnson; Fabio Pellegrini; Antonio Nicolucci; Michela Sciancalepore; Valeria Saglimbene; Letizia Gargano; Carmen Bonifati; Marinella Ruospo; Sankar D Navaneethan; Vincenzo Montinaro; Paul Stroumza; Marianna Zsom; Mariatta Torok; Eduardo Celia; Ruben Gelfman; Anna Bednarek-Skublewska; Jan Dulawa; Giusi Graziano; Giorgio Gentile; Juan Nin Ferrari; Antonio Santoro; Annalisa Zucchelli; Giorgio Triolo; Stefano Maffei; Jörgen Hegbrant; Charlotta Wollheim; Salvatore De Cosmo; Valeria M Manfreda Journal: Clin J Am Soc Nephrol Date: 2012-04-05 Impact factor: 8.237
Authors: Amirreza Azimi; Sara Hanaei; Mohammad Ali Sahraian; Mehdi Mohammadifar; Sreeram V Ramagopalan; Mahsa Ghajarzadeh Journal: Maedica (Buchar) Date: 2019-12
Authors: Jana Pöttgen; Wim van de Vis; An van Nunen; Anita Rose; Jannie Engelbrecht; Michelle Pirard; Stephanie Lau; Christoph Heesen; Sascha Köpke Journal: Int J MS Care Date: 2020-12-28